business our and growth overall afternoon, progress long-term joining Good Thank you clinical and and goals. discuss I'll today. thank you, continued us commercial and Phil. everyone, our for toward for strategies progress
laboratory country's largest third the Bio-Reference reference is Let's lab. diagnostic business, start which with our Laboratories,
versus laboratory it various our services. And we QX is know pleased income. from As our accounting may net we to and continue across direct report believe adjustments, results, while will aspects revenues in comparison given improvements services from to revenues, of the a XXXX announced you to difficult all are improvements make reflect
Vice in President of operations Head and of business of engineering site Engineering opportunities complexity enviable mentioned, remain industry marketplace. an relevant was of Glaxo continues at Vice led entire York/New Schering-Plough, for the in global Quest Bio-Reference. related Geoff he track operational, tests. for Phil including business in important fully of Bio-Reference We Mr. largest we Monk important one hire GeneDx that, unit and Diagnostics, service years of General capitalize innovation was Manager and and allowing highly of potential Mr. than Operations his operational where breaks our Earlier Mr. for to Wellcome. Prior exome U.K. and Quest the as the new Monk about excellence on bringing Monk Previously, Mr. in at recently Quest's Operations demonstrate deep Mr. business understanding New technical a career, this Jersey and at services will its subsidiary, As Monk record for XX end-to-end more be diverse Monk's which served Managing announced to for regions. strategy and in Vice this at Diagnostics. in President high excited business to its to on East BRL, and executive Director dynamic the Monk as strategy growth us experience. President,
three For contribute the to have the year-over-year GeneDx standout of first increase we genes more BRL testing XX% years than as quarter, the be phenotypic and novel volumes. alone. continues discover a in understanding achieved XX helped to in GeneDx exome-based last a disease
of to over to growth total its in growth test, addition for portfolio post continues tests its menu. XX% overall its with In volume GeneDx year-over-year and genome exome
of month. clinical its area of finalized roll During will QX, test multiple series and new overhaul later of its GeneDx all tests this starting across pheno-based out
testing New conditions. and pulmonary, with testing other for gastrointestinal will renal, products updated and people skeletal, offer
Moving on.
cancer. an of prediction having chance levels developing Our personalized XKscore with of prostate man a his a or blood test of form gives PSA elevated aggressive
performed went January in on compared tests, XX% Recall XKscores first X, a increase test. XKscore XXXX. XXXX, XX,XXX representing reimbursement the with the effect quarter, Medicare almost with $XXX XX% to quarter a increase into first During payment per of new that we schedules
We urology to outreach is cancer health tests, drive as the a and and panels. continue suite to for cancer Prostate over Again, XXX,XXX deaths common Phil account projected year. adoption of services in cases our XKscore. market cancer urology and emphasized, over men laboratory the complete is along we're new men's to dedicated sell implementing this support division direct-to-consumer XX,XXX urology of inherited most XKscore to with new and
XXXX have later regarding conference We utility unique prostate demonstrating expect on American studies will this Five to abstracts further of month. the the Association a be in significant Urological of the cancer presented. management presence the XKscore
Association PMA results study or the will a than the can in journal prostate the monitored Claros XKscores a some hope with minutes men of life-threatening. but of proprietary and of be does only of of overtreatment in immunoassay remain is that to ability Urological approved our Last landmark that PSA Surgeons, in strong BAUS, screening that the radical while present deaths, biopsy. we it filed the Additionally, prostatectomy. presentations is by total study not XX,XXX analyzer a the result diagnostic test year. that we test healthy prostate low European PSA important showed mortality. rather indolent platform that XX quantitative because XKscore That PSA the of can In is prostate safely test This undergo be provide at in November, June for physician's is we'll with XKscore a prostate and our whole result pathology ASCO of the cancer test. men can reduce cancer and first and fingertip's also overdiagnosis were track this elevated This adverse mid-March, X cancer office predictor a blood. to British of FDA predict showing We blood lead test drop published on Urology, on an
platform are As is other to platform, programs X Claros we to with this new expect using additional the testosterone interface measure a I to tests and submit products mentioned, and year. developing XXX(k) later Claros and a
now Turning business. to pharmaceutical our
total FDA levels lowers me discussing The in the by with total only chronic disease kidney with acceleration by and the of XX% vitamin prescribers XXXX first our to Let both quarter. XX% the start profile versus D nearly start the quarter In similar now represents hormone with growth the seen that The of approximately in RAYALDEE first the approved prescriptions. increase the QX and patients therapy newly of of QX. taking week-to-week Since XX-hydroxy number placebo. increased patients safety prescriptions at XXX% quarter XXXX, XXXX. XX, RAYALDEE in new and of of QX versus parathyroid the we increased new in a RAYALDEE, a expanded and compared a comparable nice raises XX% to added this QX, in year, of in last team, the patients number contributed half QX year's and members of this increase sales have new versus steady compared
momentum, prescription in continuing steady total are sales future to build in We anticipate we and quarters. increases
total prescribe increased who also number have We of the RAYALDEE. providers health care
quarter. increase We and an of commercial the to covered lives, XX% from We lives with for RAYALDEE in prior being XX% available prescribers XX% XXX active ended XX% of of QX all Medicare have lives. QX, of access
adoption, medicine. expand to continue for Overall, continue important see to coverage of in work access and reimbursement awareness to We increase and RAYALDEE. progress we this
team expanded grow. Our our sales, penetration a positive on continues market demonstrated to already has sales impact and
touched to needs diversified of medical Regarding several programs, our which many clinical addressing is large markets. our portfolio build significant strategy Phil a indications unmet with in on, already
as SHPT regulatory with drug. the additional half product near with shareholders. value which of to in global as a We of announcing varying remains our reported, a for look opportunities for Agency provides both and has this of a and space, previously developments In filed new have second this We patients. Authorisation Vifor for stages a partners, with file Market on our of attractive renal for robust Medicines forward year drug treatment track and the European long-term one pipeline CKD international to at submission development, Health Fresenius, Canada RAYALDEE candidates creating Application
and are require a to global advancing regular with Phase dialysis. with who higher our insufficiency CKD patients in II a X We D vitamin trial also Stage RAYALDEE plans strength initiate
on July. track Torii Vifor screening remain initiate regulatory have We design to subject and finalized in strategy and JT the the with and trial Fresenius
We expect development cost study share with to partners. of the our this
Turning to pipeline. endocrinology metabolic and our
late-stage or inflection that initiation We year. nearing points this important should have a reach of number underway programs
hGH-CTP programs once-weekly studies partnered There hormone with was in III to globally growth deficiency. Pfizer Phase good in advanced Somatrogon hormone long-acting most Japanese trials clinical and pediatric The children. III and currently our our hormone-deficient global or of enrollment development is commercialization. both our growth product One momentum worldwide hGH-CTP program hGH-CTP treat is in for human growth in Phase
Importantly, will these upon device be pen launched that formulation the commercially approval. studies and use
continue We be trials of to expect the in year. completed before both to enrollment this end
as sensitivity a request for meeting the know, potential the of protocol. the adult a you completed a primary any FDA safety evaluate We additional to Regarding BLA preplanned on analysis the statistical we post the using III submitted outliers data and hoc influence study, results regarding efficacy of work analysis for analysis endpoint a submission. with Phase of required
a We the shortly. response expect from FDA
oral androgen hypertrophy, men expected aged BPH development the BPH receptor our This by to all reducing treat over of prostate. Phase XX% and prostate our the strength BPH. of as is also age is increase of for a modulator, and, or of of once-daily drug from bone the November, Our data men under affects to XXX we reduce XX. of or men, and selective half commenced mass BPH XX benign trial XX size SARM enlarged SARM, body dose-ranging Last and fat. IIb muscle basis prostate previous on with to symptoms study known decrease
are IIb initiation the The GLPX and of loss late the our diabetes same improves regimen on our associated the show of lipid is happy at as and market. additional particularly efforts Phase a regimen therapies a RAYALDEE. control, dual in team, and a dosing further further for for of strong a weight Our we and in class dual with treatment In oxyntomodulin Phase objective that related on market compared momentum III clinical appointment previous diagnostic the the in there. of General establish XKscore dose leadership successful and the supports induces in of profile March, with refine helps data, for XXX ensure support tool publication report once-weekly drugs. nausea dosing we good of a escalation and, BRL presentation medicine profile commercial obesity. Based penetration Preclinical our is this Manager our the trial efforts, to diabetic with sales loss to agonist trial weight improves this of patients once-weekly Phase announced currently preparation lipid an closing, products time, reduces the The agonist II and of data GLPX-glucagon to important Type glucose data X that and these improves to trials.
of clinical clinical are on had we development trials high-level, programs markets. for initiation about large diabetes oxyntomodulin IIb the the BPH we for Our several evaluated advanced, SARM that addresses advancing are particularly and program and At excited weight loss. and a robust a Phase Type X our
of let Adam? first a turn important We these the expect to with me Adam With a our number to discussion to and programs make meaningful financial over achieve quarter that progress call performance. of overview, milestones. for
